Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T19:49:03.997Z.
Calculation as of: 2026-10-06T19:49:03.997Z.
Quote observation: 2026-10-06T19:45:24.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 73a05a26affbff61ca245286eab2f65fbc602d03c7bc752639a64992bef0efba
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| QT Imaging Holdings, Inc. (QTI) | $35.39M | N/A | N/A | N/A | N/A |
| Elicio Therapeutics, Inc. (ELTX)vs › | $35.46M | N/A | N/A | N/A | N/A |
| DocGo Inc. (DCGO)vs › | $35.15M | N/A | 8.66x | 44.05x | 43.98x |
| BriaCell Therapeutics Corp. (BCTX)vs › | $35.02M | N/A | N/A | N/A | N/A |
| Edesa Biotech, Inc. (EDSA)vs › | $36.17M | N/A | N/A | N/A | N/A |
| EUDA Health Holdings Limited (EUDA)vs › | $36.29M | N/A | N/A | N/A | N/A |
| Elutia Inc (ELUT)vs › | $34.04M | N/A | N/A | N/A | N/A |
| Grace Therapeutics, Inc. (GRCE)vs › | $33.85M | N/A | N/A | N/A | N/A |
| Aligos Therapeutics, Inc. (ALGS)vs › | $33.54M | N/A | N/A | N/A | N/A |
| Scilex Holding Company (SCLX)vs › | $33.63M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute